Chemical formula: C₁₃H₂₀N₂O₂ Molecular mass: 236.315 g/mol PubChem compound: 65859
Levodropropizine interacts in the following cases:
Animal pharmacology studies have demonstrated that levodropropizine does not potentiate the pharmacological effect of substances acting on the central nervous system (eg. benzodiazepines, alcohol, phenytoin, imipramine).
Caution is necessary in case of the concomitant intake of sedative drugs in particularly sensitive subjects.
Caution is recommended in patients with severe renal failure (creatinine clearance <35 ml/min).
Due to the inhibition of the cough reflex by levodropropizine, the concomitant administration of expectorants should be avoided, as this may lead to mucus retention in the respiratory system, potentially increasing the risk of bronchospasm and airway infection.
Teratogenesis, reproduction and fertility studies as well as peri- and post-natal studies did not reveal any specific toxic effect.
Nevertheless, as in animal toxicology studies with the 24 mg/kg dose a mild delay in the body weight increase and in growth has been observed and as levodropropizine is able to cross the placental barrier in the rat, the drug is contraindicated in women wanting to get pregnant or already pregnant as its safety of use is not documented.
Studies in rats show that the drug can be found in the mother's milk until 8 hours after administration. Thus, the drug is contraindicated during lactation.
Studies have not been performed on the ability to drive and/or the use of machines. Nevertheless, as the product may rarely cause sleepiness caution must be used in patients who intend to drive or use machines, informing them about this possibility.
During the treatment with levodropropizine palpitations, tachycardia, nausea, vomiting, diarrea, erythema could occur. The adverse reactions reported as serious are urticaria and anaphylactoid reaction.
The most reactions occur after the administration of levodropropizine are not serious and the symptoms has been solved stopping the therapy and, in some cases, with a special pharmacological treatment.
The observed adverse reactions (incidence not known) are the following:
Eye disorders: Mydriasis, bilateral blindness
Immune system disorders: Allergic and anaphylactoid reactions, eyelid oedema, angioneurotic oedema, urticaria.
Psychiatric disorders: Irritability, sleepiness, personality change or personality disorder.
Neurological disorders: Syncope, dizziness, vertigo, tremors, paresthesia, tonic-clonic convulsion. An individual case has been reported of tonic-clonic convulsions and an attack of petit mal, coma hypoglicemic.
Cardiac disorders: Palpitations, tachycardia, atrial bigeminism.
Vascular disorders: Hypotension
Respiratory, thoracic and mediastinal disorders: Dyspnoea, cough, oedema of the respiratory tract.
Gastrointestinal disorders: gastric pain, abdominal pain, nausea, vomiting,: diarrhoea. Hepatobiliary disorders: Cholestatic hepatitis
Skin and subcutaneous tissue disorders: Urticaria, erythema, exanthema, itching, angioedema, skin reactions, glossitis and aphthous stomatitis Epidermolysis.
Musculoskeletal and connective tissue disorders: Weakness of lower limbs.
General disorders and administration site conditions: General malaise, generalised oedema, asthenia.
A case of drowsiness, hypotonia and vomiting was reported in an infant after levodropropizine was taken by a nursing mother. Symptoms appeared after feeding and resolved spontaneously when breastfeeding was suspended for a few feedings.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.